Peptron, Inc.

KOSDAQ:A087010 Stock Report

Market Cap: ₩1.8t

Peptron Valuation

Is A087010 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A087010 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A087010's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A087010's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A087010?

Key metric: As A087010 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A087010. This is calculated by dividing A087010's market cap by their current book value.
What is A087010's PB Ratio?
PB Ratio84.7x
Book₩20.71b
Market Cap₩1.75t

Price to Book Ratio vs Peers

How does A087010's PB Ratio compare to its peers?

The above table shows the PB ratio for A087010 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5x
A141080 LigaChem Biosciences
5.7x98.8%₩3.6t
A220100 FutureChemLtd
6.3xn/a₩371.0b
A445680 Curiox Biosystems
6.4xn/a₩312.3b
A278650 HLB bioStepLtd
1.5xn/a₩176.8b
A087010 Peptron
84.7xn/a₩1.8t

Price-To-Book vs Peers: A087010 is expensive based on its Price-To-Book Ratio (84.7x) compared to the peer average (5x).

Price to Book Ratio vs Industry

How does A087010's PB Ratio compare vs other companies in the KR Life Sciences Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
A225220 Genolution
0.5xn/aUS$32.22m
A043090 TechnologyLtd
0.6xn/aUS$17.50m
No more companies available in this PB range
A087010 84.7xIndustry Avg. 1.4xNo. of Companies7PB02.44.87.29.612+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A087010 is expensive based on its Price-To-Book Ratio (84.7x) compared to the KR Life Sciences industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is A087010's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A087010 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio84.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A087010's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

7D

6.0%

1Y

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

7D

-3.4%

1Y

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

7D

-2.0%

1Y

8.6%